The Week in Cancer News: Cholangiocarcinoma Therapy and Lung Cancer Treatment Rates
The FDA approved a therapy for bile duct cancer, and most older adults with stage IV lung cancer never receive systemic treatment.
Progress Against Cancer
The FDA approved a therapy for bile duct cancer, and most older adults with stage IV lung cancer never receive systemic treatment.
The FDA approved oral decitabine and cedazuridine with venetoclax for newly diagnosed acute myeloid leukemia in older patients. The U.S. Food and Drug Administration (FDA) approved oral tablets of decitabine and cedazuridine (Inqovi) in...
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult...
An AACR grant to study menin's structure gave researchers the 3D map they needed to produce new treatments for acute myeloid leukemia.
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin 1 gene. The U.S. Food and Drug Administration (FDA) approved zenocutuzumab-zbco (Bizengri) for the treatment...
Findings signal targeted therapy effectiveness in pancreatic cancer, and new insights into the thymus’s role in cancer and health.
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to be priorities.
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu) for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced...
Heart, kidney and metabolic conditions may be linked to higher cancer risk, and a pooled cord blood therapy was found safe and similarly effective as traditional transplant in blood cancers.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More